PT  - JOURNAL ARTICLE
AU  - Ariel Israel
AU  - Yotam Shenhar
AU  - Ilan Green
AU  - Eugene Merzon
AU  - Avivit Golan-Cohen
AU  - Alejandro A Schäffer
AU  - Eytan Ruppin
AU  - Shlomo Vinker
AU  - Eli Magen
TI  - Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection
AID  - 10.1101/2021.08.19.21262111
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.19.21262111
4099  - http://medrxiv.org/content/early/2021/08/22/2021.08.19.21262111.short
4100  - http://medrxiv.org/content/early/2021/08/22/2021.08.19.21262111.full
AB  - Background Immune protection following either vaccination or infection with SARS-CoV-2 decreases over time.Objective To determine the kinetics of SARS-CoV-2 IgG antibodies following administration of two doses of BNT162b2 vaccine, or SARS-CoV-2 infection in unvaccinated individuals.Methods Antibody titers were measured between January 31, 2021, and July 31, 2021 in two mutually exclusive groups: i) vaccinated individuals who received two doses of BNT162b2 vaccine and had no history of previous infection with COVID-19 and ii) SARS-CoV-2 convalescents who had not received the vaccine.Results A total of 2,653 individuals fully vaccinated by two doses of vaccine during the study period and 4,361 convalescent patients were included. Higher SARS-CoV-2 IgG antibody titers were observed in vaccinated individuals (median 1581 AU/mL IQR [533.8-5644.6]) after the second vaccination, than in convalescent individuals (median 355.3 AU/mL IQR [141.2-998.7]; p<0.001). In vaccinated subjects, antibody titers decreased by up to 40% each subsequent month while in convalescents they decreased by less than 5% per month. Six months after BNT162b2 vaccination 16.1% subjects had antibody levels below the seropositivity threshold of <50 AU/mL, while only 10.8% of convalescent patients were below <50 AU/mL threshold after 9 months from SARS-CoV-2 infection.Conclusions This study demonstrates individuals who received the Pfizer-BioNTech mRNA vaccine have different kinetics of antibody levels compared to patients who had been infected with the SARS-CoV-2 virus, with higher initial levels but a much faster exponential decrease in the first group.Funding This research was internally funded by Leumit Health Services (LHS) and was supported in part by the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research.The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.Impact statement Large scale study display the kinetics of SARS-CoV-2 IgG antibodies present in individuals vaccinated with two doses of mRNA vaccine vs. unvaccinated patients who had recovered from the disease: initial levels of antibody are much higher in vaccinated patients, but decrease faster.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was internally funded by Leumit Health Services (LHS) and was supported in part by the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by Shamir Medical Center Institutional Review Board (129-2-LEU).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData were obtained from patients' electronic health records, and IRB approval restrains its use to researchers inside Leumit Health Services.COVID-19Coronavirus disease of 2019SARS-CoV-2Severe acute respiratory syndrome coronavirus 2mRNAMessenger RNALHSLeumit Health ServicesHMOHealth maintenance organizationSESSocio-economic statusBMIBody mass IndexIQRInterquartile rangeRT-PCRReverse transcription polymerase chain reactionIgGImmunoglobulin GBMPCsBone marrow plasma cellsACE2Angiotensin-converting enzyme 2